Swedish Orphan Biovitrum presents first positive Kiobrina clinical phase II data

10-May-2010 - Sweden

Swedish Orphan Biovitrum presented clinical phase II results from the first study showing that Kiobrina® added to infant formula significantly improve growth of preterm infants as compared to placebo after 1 week of treatment.

"This is an interesting project and Kiobrina holds a great opportunity to fill a medical need in neonatal care. Based on these results and those from a second clinical phase II trial of Kiobrina in pasteurized mother's milk we are now planning for a phase III study in preterm infants", said Peter Edman, CSO of Swedish Orphan Biovitrum

Kiobrina is a recombinant human bile-salt-stimulated lipase (rhBSSL) developed by Swedish Orphan Biovitrum, aiming to improve growth and development in preterm infants. The rationale for adding rhBSSL to pasteurized breast milk or infant formula is to restore the natural lipase activity level that is either lost on pasteurization or totally absent in formula.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances